Accuray approval for Tomo C in China a ‘tremendous milestone,’ says Lake Street

After Accuray announced that the registration dossier for the CNNC-Accuray joint venture Tomo C radiation therapy system for the Type B market has been approved by the Chinese National Medical Products Administration, Lake Street analyst Brooks O’Neil said this “tremendous milestone” opens the door to a “vast, underserved, global value-segment of the radiation therapy market Accuray has never previously addressed.” The firm, which said the news came a few months earlier than it had expected, is not changing its forecast for Accuray at this time and affirms its Buy rating and $13 price target on the shares.